Antiepileptic drugs. Advantages and disadvantages

Handbook of Clinical Neurology

Volumn 108, Issue , 2012, Pages 723-739

  Abou Khalil, Bassel ^a   Schmidt, dieter ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Adverse effects; Antiepileptic drugs; Effectiveness; Efficacy; Tolerability

Indexed keywords

EID: 84865598516     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52899-5.00024-1     Document Type: Chapter

References (99)

1. Albani F., Grassi B., Ferrara R., et al. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure 2004, 13:254-263.
2. Alvestad S., Lydersen S., Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007, 48:1360-1365.
3. Armon C., Shin C., Miller P., et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996, 47:626-635.
4. Azar N.J., Abou-Khalil B.W. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Semin Neurol 2008, 28:305-316.
5. Beghi E., Gatti G., Tonini C., et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003, 57:1-13.
6. Ben-Menachem E. Weight issues for people with epilepsy: a review. Epilepsia 2007, 48:42-45.
7. Benedetti M.S. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000, 14:301-319.
8. Berkovic S.F., Knowlton R.C., Leroy R.F., et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007, 69:1751-1760.
9. Bermejo P.E., Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol 2008, 32:103-106.
10. Besag F.M., Berry D.J., Pool F., et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998, 39:183-187.
11. Beydoun A., Fischer J., Labar D.R., et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997, 49:746-752.
12. Biton V., Montouris G.D., Ritter F., et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999, 52:1330-1337.
13. Biton V., Sackellares J.C., Vuong A., et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005, 65:1737-1743.
14. Brighina F., Palermo A., Aloisio A., et al. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol 2006, 29:338-342.
15. Brodie M.J., Yuen A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997, 26:423-432.
16. Brodie M.J., Richens A., Yuen A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995, 345:476-479.
17. Brodie M.J., Overstall P.W., Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999, 37:81-87.
18. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
19. Browne T.R., Feldman R.G., Buchanan R.A., et al. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology 1983, 33:414-418.
20. Callaghan B.C., Anand K., Hesdorffer D., et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007, 62:382-389.
21. Christensen J., Pedersen M.G., Pedersen C.B., et al. Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 2009, 373:1105-1110.
22. Coppola G., Franzoni E., Verrotti A., et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev 2007, 29:281-284.
23. Corda D., Gelisse P., Genton P., et al. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001, 42:754-759.
24. Cramer J.A., Leppik I.E., Rue K.D., et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003, 56:135-145.
25. Crespel A., Genton P., Berramdane M., et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005, 65:762-764.
26. Cross J.H. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002, 11:406-410.
27. Cunnington M., Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005, 64:955-960.
28. Dam M., Ekberg R., Loyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989, 3:70-76.
29. Eldridge R., Iivanainen M., Stern R., et al. " Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983, 2:838-842.
30. Elger C.E., Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008, 12:501-539.
31. Engel J.J., Pedley T. Epilepsy: A Comprehensive Textbook 2007, Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia.
32. Felbamate Study Group LGS Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 1993, 328:29-33.
33. Ferrendelli J.A., French J., Leppik I., et al. Use of levetiracetam in a population of patients aged 65years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003, 4:702-709.
34. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401-409.
35. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. II. Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:410-423.
36. Gelisse P., Genton P., Kuate C., et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004, 45:1282-1286.
37. Genton P., Gelisse P., Thomas P., et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?. Neurology 2000, 55:1106-1109.
38. Glauser T.A., Levisohn P.M., Ritter F., et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000, 41:S86-S90.
39. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
40. Glauser T.A., Cnaan S., Shinnar S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
41. Glauser T.A., Dlugos D.J., Dodson W.E., et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 2007, 22:693-699.
42. Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
43. Guerrini R., Dravet C., Genton P., et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998, 39:508-512.
44. Hauser W.A. The natural history of drug resistant epilepsy: epidemiologic considerations. Epilepsy Res Suppl 1992, 5:25-28.
45. Isojarvi J.I., Huuskonen U.E., Pakarinen A.J., et al. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001, 42:741-745.
46. Isojarvi J.I., Tauboll E., Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005, 19:207-223.
47. Jamora D., Lim S.H., Pan A., et al. Valproate-induced parkinsonism in epilepsy patients. Mov Disord 2007, 22:130-133.
48. Jensen R., Brinck T., Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994, 44:647-651.
49. Kim L.G., Johnson T.L., Marson A.G., et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006, 5:317-322.
50. Kinirons P., McCarthy M., Doherty C.P., et al. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 2006, 15:387-392.
51. Kothare S.V., Valencia I., Khurana D.S., et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004, 6:267-270.
52. Krauss G.L., Betts T., Abou-Khalil B., et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003, 12:617-620.
53. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
54. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
55. Kwan P., Brodie M.J. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004, 45:1141-1149.
56. Levy R.H., Mattson R.H., Meldrum B., et al. Antiepileptic Drugs 2002, Lippincott, Williams & Wilkins, Philadelphia.
57. Löscher W., Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006, 47:1253-1284.
58. Löscher W., Klotz U., Zimprich F., et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 50:1-23.
59. Marson A., Jacoby A., Johnson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005, 365:2007-2013.
60. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
61. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
62. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119-128.
63. Mattson R.H., Cramer J.A., Collins J.F., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985, 313:145-151.
64. Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992, 327:765-771.
65. Meador K., Reynolds M.W., Crean S., et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008, 81:1-13.
66. Mikati M.A., Holmes G.L. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997, 12:S29-S37.
67. Motte J., Trevathan E., Arvidsson J.F., et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997, 337:1807-1812.
68. Mula M., Trimble M.R., Sander J.W. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007, 48:2322-2326.
69. Nicolson A., Appleton R.E., Chadwick D.W., et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004, 75:75-79.
70. Noachtar S., Andermann E., Meyvisch P., et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
71. Ohman I., Beck O., Vitols S., et al. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008, 49:1075-1080.
72. Ohtahara S. Zonisamide in the management of epilepsy-Japanese experience. Epilepsy Res 2006, 68:S25-S33.
73. Ortenzi A., Paggi A., Foschi N., et al. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy. Funct Neurol 2008, 23:97-100.
74. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347-356.
75. Picard F., Bertrand S., Steinlein O.K., et al. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 1999, 40:1198-1209.
76. Prasad A., Kuzniecky R.I., Knowlton R.C., et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003, 60:1100-1105.
77. Privitera M.D., Brodie M.J., Mattson R.H., et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003, 107:165-175.
78. Raju G.P., Sarco D.P., Poduri A., et al. Oxcarbazepine in children with nocturnal frontal-lobe epilepsy. Pediatr Neurol 2007, 37:345-349.
79. Ristic A.J., Vojvodic N., Jankovic S., et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006, 47:2183-2185.
80. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64:1868-1873.
81. Saetre E., Perucca E., Isojarvi J., et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007, 48:1292-1302.
82. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008, 70:54-65.
83. Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav 2009, 15:56-65.
84. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
85. Selwa L.M., Schmidt S.L., Malow B.A., et al. Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia 2003, 44:1568-1572.
86. Sharpe D.V., Patel A.D., Abou-Khalil B., et al. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure 2008, 17:64-68.
87. Shorvon S. Handbook of Epilepsy Treatment 2000, Blackwell Science, Oxford.
88. Silberstein S.D., Lipton R.B., Dodick D.W., et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170-180.
89. Sillanpää M., Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006, 129:617-624.
90. Sillanpää M., Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009, 132:989-998.
91. Snead O.C., Hosey L.C. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985, 313:916-921.
92. Temkin N.R. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 2009, 50:10-13.
93. Vajda F.J., O'Brien T.J., Hitchcock A., et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004, 11:854-858.
94. Verrotti A., Cerminara C., Domizio S., et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol 2008, 50:850-853.
95. Wheless J.W. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000, 15:S7-S13.
96. Wilder B.J., Buchanan R.A. Methsuximide for refractory complex partial seizures. Neurology 1981, 31:741-744.
97. Wilfong A., Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005, 64:31-34.
98. Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004, 13:S41-S48. discussion S49.
99. Zaccara G., Franciotta D., Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007, 48:1223-1244.